Emmanouil Fokas1,2,3, Philipp Ströbel4, Rainer Fietkau5, Michael Ghadimi6, Torsten Liersch6, Gerhard G Grabenbauer7, Arndt Hartmann8, Marco Kaufmann9, Rolf Sauer5, Ullrich Graeven10, Hans Hoffmanns11, Hans-Rudolf Raab12, Torsten Hothorn9, Christian Wittekind13, Claus Rödel1,2,3. 1. Department of Radiotherapy and Oncology, University of Frankfurt, Frankfurt, Germany. 2. German Cancer Research Center (DKFZ), Heidelberg, Germany. 3. German Cancer Consortium (DKTK), partner site: Frankfurt/Mainz, Heidelberg, Germany. 4. Institute of Pathology, University Medical Center Göttingen, Göttingen, Germany. 5. Department of Radiation Therapy, University of Erlangen-Nürnberg, Nürnberg, Germany. 6. Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany. 7. Department of Radiation Oncology and Radiotherapy, DiaCura and Klinikum Coburg, Coburg, Germany. 8. Institute of Pathology. 9. Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland. 10. Department of Hematology/Oncology and Gastroenterology, Kliniken Maria Hilf GmbH Mönchengladbach, Mönchengladbach, Germany. 11. Department of Radiation Oncology, Kliniken Maria Hilf GmbH Mönchengladbach, Mönchengladbach, Germany. 12. Department of General and Visceral Surgery, University of Oldenburg, Oldenburg, Germany. 13. Institute of Pathology, University of Leipzig, Leipzig, Germany.
Abstract
Background: We investigated tumor regression grading (TRG) as a prognostic marker and individual-level surrogate for disease-free survival (DFS) in patients with rectal carcinoma treated within the Chirurgische Arbeitsgemeinschaft fur Onkologie/Arbeitsgemeinschaft Radiologische Onkologie/Arbeitsgemeinschaft Internistische Onkologie (CAO/ARO/AIO)-04 randomized trial. Methods:TRG was recorded prospectively using the Dworak classification in 1179 patients after preoperativefluorouracil-based chemoradiotherapy (CRT) with or without oxaliplatin. Multivariable analysis was performed using Cox regression models adjusted for treatment arm, resection status, and pathologic stage. Individual-level surrogacy of TRG for DFS was examined using the four Prentice criteria (PC1-4). All statistical tests were two-sided. Results: With a median follow-up of 50 months, the addition of oxaliplatin to fluorouracil-based CRT led to statistically significantly improved three-year DFS (75.9%, 95% CI = 72.3 to 79.5, vs 71.3%, 95% CI = 67.6 to 74.9, P = .04, PC 1) and a shift toward more advanced TRG groups ( P < .001, PC 2) compared with CRT with fluorouracil alone. The three-year DFS was 64.6% (95% CI = 57.3 to 71.9), 77.6% (95% CI = 74.5 to 80.7), and 92.3% (95% CI = 88.4 to 96.2) for TRG 0 + 1 (poor regression), TRG 2 + 3 (intermediate regression), and TRG 4 (complete regression), respectively ( P < .001, PC 3). TRG constituted an independent prognostic factor for DFS (TRG 2 + 3 vs TRG 0 + 1, HR = 0.68, 95% CI = 0.51 to 0.90, P = .007). Due to multicollinearity, TRG 4 and pathologic stage could not be tested within the same model. The treatment effect on DFS was captured by TRG, satisfying individual-level PC4. Conclusions: Higher TRG after preoperative CRT predicted a favorable long-term outcome. At the individual patient level, TRG was a surrogate marker for DFS. Further phase III trials are needed to validate TRG as a surrogate at trial level.
RCT Entities:
Background: We investigated tumor regression grading (TRG) as a prognostic marker and individual-level surrogate for disease-free survival (DFS) in patients with rectal carcinoma treated within the Chirurgische Arbeitsgemeinschaft fur Onkologie/Arbeitsgemeinschaft Radiologische Onkologie/Arbeitsgemeinschaft Internistische Onkologie (CAO/ARO/AIO)-04 randomized trial. Methods:TRG was recorded prospectively using the Dworak classification in 1179 patients after preoperative fluorouracil-based chemoradiotherapy (CRT) with or without oxaliplatin. Multivariable analysis was performed using Cox regression models adjusted for treatment arm, resection status, and pathologic stage. Individual-level surrogacy of TRG for DFS was examined using the four Prentice criteria (PC1-4). All statistical tests were two-sided. Results: With a median follow-up of 50 months, the addition of oxaliplatin to fluorouracil-based CRT led to statistically significantly improved three-year DFS (75.9%, 95% CI = 72.3 to 79.5, vs 71.3%, 95% CI = 67.6 to 74.9, P = .04, PC 1) and a shift toward more advanced TRG groups ( P < .001, PC 2) compared with CRT with fluorouracil alone. The three-year DFS was 64.6% (95% CI = 57.3 to 71.9), 77.6% (95% CI = 74.5 to 80.7), and 92.3% (95% CI = 88.4 to 96.2) for TRG 0 + 1 (poor regression), TRG 2 + 3 (intermediate regression), and TRG 4 (complete regression), respectively ( P < .001, PC 3). TRG constituted an independent prognostic factor for DFS (TRG 2 + 3 vs TRG 0 + 1, HR = 0.68, 95% CI = 0.51 to 0.90, P = .007). Due to multicollinearity, TRG 4 and pathologic stage could not be tested within the same model. The treatment effect on DFS was captured by TRG, satisfying individual-level PC4. Conclusions: Higher TRG after preoperative CRT predicted a favorable long-term outcome. At the individual patient level, TRG was a surrogate marker for DFS. Further phase III trials are needed to validate TRG as a surrogate at trial level.
Authors: Kasun Wanigasooriya; Joao D Barros-Silva; Louise Tee; Mohammed E El-Asrag; Agata Stodolna; Oliver J Pickles; Joanne Stockton; Claire Bryer; Rachel Hoare; Celina M Whalley; Robert Tyler; Toritseju Sillo; Christopher Yau; Tariq Ismail; Andrew D Beggs Journal: Front Oncol Date: 2022-07-04 Impact factor: 5.738
Authors: Ji Hun Choi; Jae Hyun Kim; Do Hyeong Lee; Sanghwan Byun; Kyoungwon Jung; Sung Eun Kim; Won Moon; Moo In Park; Seun Ja Park Journal: J Gastrointest Oncol Date: 2019-12
Authors: Séan M O'Cathail; Steven Davis; Jane Holmes; Richard Brown; Kerry Fisher; Leonard Seymour; Richard Adams; James Good; David Sebag-Montefiore; Tim Maughan; Maria A Hawkins Journal: Radiat Oncol Date: 2020-06-12 Impact factor: 3.481